The Fort Worth Press - Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

USD -
AED 3.672504
AFN 64.999947
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 918.000346
ARS 1543.749989
AUD 1.479279
AWG 1.8
AZN 1.698907
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.674898
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.427855
CDF 2314.999626
CHF 0.839255
CLF 0.02536
CLP 998.102442
CNY 6.67175
CNH 6.66703
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.15145
DJF 178.554905
DKK 6.780703
DOP 60.996961
DZD 136.947837
EGP 53.746403
ERN 15
ETB 164.576405
EUR 0.906897
FJD 2.280097
FKP 0.756558
GBP 0.756725
GEL 2.589744
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 73.999911
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84575
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 330.860995
IDR 18278.7
ILS 3.21885
IMP 0.756558
INR 93.89345
IQD 1520.102326
IRR 1913737.49877
ISK 123.889854
JEP 0.756558
JMD 158.434973
JOD 0.709017
JPY 159.415987
KES 129.930041
KGS 87.435499
KHR 4119.418691
KMF 446.999696
KPW 900.00035
KRW 1333.240543
KWD 0.31144
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.826123
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809799
MVR 15.402598
MWK 1738.739965
MXN 18.57305
MYR 4.092402
MZN 63.898524
NAD 16.951268
NGN 1345.469832
NIO 36.903315
NOK 9.583895
NPR 151.114437
NZD 1.81158
OMR 0.384504
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.952022
PKR 277.274459
PLN 3.99508
PYG 6223.068898
QAR 3.655265
RON 4.852499
RSD 106.666028
RUB 82.504138
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.81956
SDG 601.498022
SEK 10.0626
SGD 1.288215
SHP 0.752984
SLE 23.050158
SLL 20969.503664
SOS 573.051087
SRD 37.49007
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.886505
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392165
TTD 6.806306
TWD 32.921501
TZS 2652.574003
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25765
VUV 120.719595
WST 2.810584
XAF 594.885499
XAG 0.021034
XAU 0.00025876167
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 594.885499
XPF 108.186074
YER 236.550111
ZAR 16.91872
ZMK 9001.201274
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084149
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.

Text size:

Silver-based medical treatments represent a rapidly growing market, with the silver wound dressings segment valued at $1.03 billion in 2024 and projected to reach $1.36 billion by 2030 (Grand View Research, 2024) ¹. Additionally, the antimicrobial coatings market-which includes silver-infused medical devices, hospital surfaces, and implants-is expected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, at a CAGR of 14.2% (Verified Market Research, 2024) ².

Why Silver(II) Has Enhanced Healing Properties

Silver has long been used in medicine for its antimicrobial effects, particularly in wound care, burn treatment, and medical coatings. Silver(II) (Ag²⁺) is a rare oxidation state of silver, as silver typically exists in the +1-oxidation state Silver(I) (Ag⁺). While Silver(I) compounds have demonstrated strong antibacterial activity, Silver(II) offers significantly enhanced healing potential due to its greater oxidative capacity, broader bactericidal activity, and potential role in tissue regeneration.

  • More Potent Antimicrobial Action - Silver(II) is a stronger oxidizing agent than Silver(I), meaning it disrupts bacterial cell membranes, proteins, and DNA more aggressively, leading to rapid bacterial cell death. Unlike Silver(I), which primarily interacts with bacterial surfaces, Silver(II) generates reactive oxygen species (ROS) that can penetrate biofilms and kill even antibiotic-resistant bacteria.

  • Accelerated Wound Healing - Silver(II) has been observed to stimulate fibroblast activity and scaring processes, which are essential for collagen production and tissue repair. Additionally, its ability to upregulate vascular endothelial growth factor (VEGF) supports the formation of new blood vessels, increasing oxygen and nutrient delivery to damaged tissues.

  • Anti-Inflammatory and Immune-Modulating Properties - Silver(II) may reduce excessive inflammation by suppressing pro-inflammatory cytokines that contribute to delayed healing in chronic wounds. Studies suggest that Silver(II) may also help balance immune responses, promoting a more favorable healing environment.

Despite these advantages, Silver(II) has not been effectively used in medicine due to its extreme instability and rapid degradation-until now.

Solving the Challenge of Silver(II) Stability

While some chemical methods-such as fluorosulfates, tetraazamacrocyclic ligands, and heterocyclic amines-have briefly stabilized Silver(II) in controlled lab conditions, these approaches are not viable for biological applications due to toxicity, instability, and lack of controlled release.

Telomir-1 has the potential to be the first known biologically compatible carrier capable of stabilizing Silver(II) for medical applications, overcoming a key limitation that has historically prevented its use in healthcare.

Expanding Medical Applications with Telomir-1

By the potential to stabilizing both Silver(I) and Silver(II) in controlled-release formulations, Telomir-1 may enable new and more effective treatments in key medical areas, including:

  • Burn and wound care - Silver-based dressings are widely used to prevent infections in severe burns and open wounds. A stabilized Silver(II) formulation could enhance antimicrobial efficacy and accelerate healing.

  • Chronic wound management - Diabetic ulcers, MRSA skin infections, and post-surgical wounds could benefit from a longer-lasting, more potent silver-based therapy.

  • Medical device coatings - Silver-infused hospital surfaces, implants, and catheters could provide sustained antimicrobial protection, reducing the risk of hospital-acquired infections.

Unlocking a Multi-Billion-Dollar Market

"The ability to stabilize Silver(II) in a controlled and biologically relevant way is a game-changing scientific achievement," said Erez Aminov, Chairman & CEO of Telomir. "This discovery extends Telomir-1's capabilities beyond age-related conditions and into high-value medical applications that were previously unattainable. Given the size and rapid growth of the silver-based medical market, Silver(II) complexed-Telomir-1 could become a key player in advancing next-generation therapeutics for infection control, wound healing, and more."

Scientific Validation from Telomir's Experts

"The ability to stabilize Silver(II) has been considered nearly impossible due to its extreme reactivity and rapid degradation," said Dr. Itzchak Angel, Ph.D., Chief Scientific Advisor of Telomir. "What we have achieved with Telomir-1 represents a significant leap forward in material science and medical chemistry. By successfully stabilizing Silver(II) in a biologically compatible form, we may have unlocked the potential for a new class of therapeutics capable of transforming topical antimicrobial treatments, accelerating wound healing, and enhancing infection control. This is more than just a scientific breakthrough-it is the first step toward potentially reshaping how silver-based medicine is used in modern healthcare."

Dr. Alex Weisman, Ph.D. in Chemistry and Scientific Advisor at Telomir, added: "Silver has long been recognized for its antimicrobial properties, but until now, the industry has been limited to working with Silver(I) due to the extreme instability of Silver(II). Telomir-1's ability to complex with Silver(II) provides an unprecedented solution, allowing us to harness the full potential of Silver(II) in a controlled, biologically safe manner. This opens potential new avenues for silver-based therapeutics that were previously out of reach."

Telomir is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

References:

  1. Grand View Research (2024). "Silver Wound Dressing Market Size & Share Report." Retrieved from: https://www.grandviewresearch.com/industry-analysis/silver-wound-dressing-market

  2. Verified Market Research (2024). "Antimicrobial Coatings Market Report." Retrieved from: https://www.verifiedmarketresearch.com/product/antimicrobial-coatings-market/

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.



View the original press release on ACCESS Newswire

A.Maldonado--TFWP